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Abstract
Background: De ci si on make rs nee d to have Canadian-specific cost information in order to
develop an accurate picture of diabetes management. The objective of this study is to estimate
direct medical costs of managing complications of diabetes. Complication costs were estimated by
applying unit costs to typical resource use profiles. For each complication, the event costs refer to
those associated with the acute episode and subsequent care in the first year. State costs are the
annual costs of continued management. Data were obtained from many Canadian sources, including
the Ontario Case Cost Project, physician and laboratory fee schedules, formularies, reports, and
literature. All costs are expressed in 2000 Canadian dollars.
Results: Major events (e.g., acute myocardial infarction: $18,635 event cost; $1,193 state cost),
generate a greater financial burden than early stage complications (e.g., microalbuminuria: $62
event cost; $10 state cost). Yet, complications that are initially relatively low in cost (e.g.,
microalbuminuria) can progress to more costly advanced stages (e.g., end-stage renal disease,
$63,045 state cost).
Conclusions: Macrovascular and microvascular complication costs should be included in any
economic analysis of diabetes. This paper provides Canadian-based cost information needed to
inform critical decisions about spending limited health care dollars on emerging new therapies and
public health initiatives.
Background
Diabetes mellitus is a chronic disorder that has been rec-
ognized by the Canadian government as a major public
health problem with far reaching consequences not just
for its adverse impact on the health of Canadians, but also
for the economic burden it places on the health care sys-
tem. In recognition of the seriousness of the problem,
over 100 million dollars has been set aside to fund the Ca-
nadian Diabetes Strategy – a comprehensive national plan
focusing on the prevention of diabetes through health
promotion and education [1]. Targeting diabetes in this
way is not surprising as it has been estimated that over 1
million Canadians are known to be afflicted with this con-
dition, with 90% having type 2 diabetes [2]. Furthermore,
it is acknowledged that this is likely an underestimation of
the scope of the disease as up to 1 in 2 persons with dia-
betes do not know they have it [3].
The clinical consequences of diabetes can be life threaten-
ing and disabling. Diabetes is ranked as the seventh lead-
ing cause of death in Canada with at least 5,500 deaths per
year attributed directly to the condition itself; however,
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this number rises dramatically to approximately 25,000
when deaths from diabetic complications are included
[1]. Coronary heart disease is the leading cause of death in
patients with diabetes [3].
There is an established connection between diabetes and
both macrovascular and microvascular complications [4–
6]. It has been reported that in Canada 21% of patients
with diabetes have heart disease [7] and that 25% of all
cardiac surgery can be attributed to diabetes. It is also the
leading cause of both end-stage renal disease (ESRD) and
non-traumatic lower extremity amputations (LEAs) in
Canada, accounting for 32% and 50% of new cases, re-
spectively [8,9]. Four hundred new cases of blindness can
be attributed to diabetes each year, making diabetes the
leading cause of new blindness in Canadian adults [10].
Many of the complications of diabetes are particularly de-
bilitating to the patient, accompanied not only by a per-
sonal physical and emotional burden, but a significant
economic one for the patient, family members, the nation
as a whole and the health care system in particular. Health
Canada has reported that twice as many patients with di-
abetes of working age reported disability days in a set pe-
riod than their non-diabetic contemporaries [7].
In 1993, the economic burden of diabetes to Canada was
estimated at $1.1 billion annually [11]. It has been ac-
knowledged that this is a gross underestimation as costs
related to the complications of diabetes were not included
[7]. A later projection of $9 billion (US$) annually, which
included both direct and indirect costs was established
[6]. This estimate was derived, however, based on pub-
lished studies from the United States (US) and by making
adjustments for differences in population sizes between
the two countries. Given the sources for this estimate, it
could be argued that it does not accurately reflect the cost
of diabetes for Canada. Yet, it is not uncommon to see US-
based proxy costs in Canadian reports, as there is a
marked lack of Canadian-specific cost information relat-
ing to diabetes and its complications in the literature.
Given the recent initiatives of the Canadian government
to target diabetes at a national level, diabetes and its com-
plications are clearly an ongoing concern for health care
decision makers. To make informed decisions about dia-
betes-related care and new therapeutic interventions, such
as emerging oral hypoglycemics, these decision makers
need to have Canadian-specific cost information. Moreo-
ver, to ensure an accurate picture of the cost of managing
diabetes the typical broad cost estimates are not useful be-
cause they do not distinguish among determinants of re-
source use and their time course and thus cannot help sort
out the implications of changes in policy. For example, if
a new drug is more expensive but reduces the frequency of
hyperglycemia then its economic assessment must ad-
dress costs at a more detailed level. Building on our previ-
ously published work on the Canadian costs of major
macrovascular complications of diabetes [12], the aim of
this paper is to provide key pieces of that complex eco-
nomic puzzle. This paper presents updated Canadian-spe-
cific cost information for macrovascular complications
and new information on microvascular complications.
The complications included in the analysis were chosen
based on those considered in published epidemiological
and economic models of diabetes [13–15]. Data are pre-
sented in a comprehensive manner so that researchers can
examine the cost per patient for each complication.
Methods
It must be noted that the cost estimates presented are not
the total costs due to these complications for the Canadi-
an diabetic population, but rather, the typical costs of key
components in an episode of illness. Average per-patient
total costs were estimated by applying unit costs to the
likely course of treatment for each complication. The mac-
rovascular complications considered in this analysis are
acute myocardial infarction(AMI), angina pectoris,
ischemic stroke, and transient ischemic attacks (TIA). Mi-
crovascular complications include various levels of neph-
ropathy (i.e., microalbuminuria, gross proteinuria,
ESRD), retinopathy (i.e., proliferative retinopathy, macu-
lar edema, blindness), symptomatic neuropathy, LEA,
and foot ulcers. While LEA and foot ulcers have been con-
sidered as neuropathic microvascular complications in
this analysis, there is also a macrovascular component to
these complications. Hypoglycemia was also considered
as an acute complication.
The methodology and format used for developing and
presenting the cost estimates in this paper have been pub-
lished in earlier papers addressing the same complications
for the U.S., and major macrovascular costs in Canada
[12,16]. The cost of each complication is reported sepa-
rately for the "event" and for the subsequent "state". Event
costs are those associated with resource use specific to the
defining clinical event and include both acute care (initial
management in an inpatient or outpatient setting) and
event-related health care delivered subsequently in the
first year. This care may include subacute inpatient care
(i.e., rehabilitation units within an acute care hospital, re-
habilitation hospitals, nursing home facilities), home
health care, outpatient therapy, physician visits, day care
and diagnostic and therapeutic procedures, depending on
the complication addressed.
For many of the complications, the resulting management
costs persist after the event because it has placed the pa-
tient in a new health state. For these complications it is
important to consider the ongoing, or state, costs. The
state costs presented in this paper refer to the annualBMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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management costs for years subsequent to the event year
and reflect the typical utilization of health care services for
the ongoing management of the given health state. Some
of the complications (i.e., foot ulcers, hypoglycemia)
however, may not have a permanent effect on a person's
health state, as they are potentially reversible and thus ep-
isodic events that can occur more than once. Given that
these conditions are limited in duration, only event costs
are applicable and no state costs are reported.
All event and state costs reported in this paper are incre-
mental to any recommended measures that take place as
part of routine diabetes management, the costs of which
are not included in this analysis.
Cost Sources
As no one data source was available from which to ab-
stract resource use and cost-relevant data for this analysis,
it was necessary to gather information from a variety of
pertinent sources. Acute inpatient resource use and costs
were derived primarily from the 1994–95 and 1995–96
Ontario Case Cost Project (OCCP) databases [17,18].
OCCP is a joint program of the Ontario Ministry of
Health and the Ontario Hospital Association. It was initi-
ated for the purpose of developing information based on
case cost data for funding and hospital management pur-
poses. Patients with the analysis-relevant complications
were identified by a principal diagnosis code (Table 1) us-
ing International Classification of Diseases (ICD-9) codes
[19]. Where possible, only patients with a secondary diag-
nosis code of diabetes were included in the analysis. For
example, diabetic patients admitted primarily for AMI
were identified by a principal diagnosis code of AMI (ICD-
9: 410.0–410.9) and a secondary diagnosis code docu-
menting diabetes (ICD9:250.00–250.93). When the
number of diabetic patients with a specific complication
was insufficient to perform a reliable analysis, the popula-
tion was expanded to include non-diabetic patients with
that complication, as the focus of the analysis was to de-
velop the cost of managing the complication and not dia-
betes. Additional cost-related information based on Case
Mix Groupings (CMGs) for 1996 [20] was also reviewed
and used when necessary to supplement the ICD9-based
data. Acute care hospital cost estimates include, all accom-
modation (e.g., routine and special care units), ancillary
services (e.g., pharmacy, laboratory), emergency room,
operating room, diagnostic and therapeutic procedures,
and physician costs. As physician costs are not included in
the OCCP data nor reported in the literature in sufficient
detail, it was necessary to develop the corresponding re-
source use profiles. The OCCP data and the medical liter-
ature were used to develop these based on length of stay
(LOS), physician service data, and the use of resource in-
tensive services such as the emergency room, surgical pro-
cedures such as LEA, special care units, and consultations.
Recognizing the need for continuation of health care serv-
ices upon discharge, post-acute care resource use profiles
were developed. To develop these profiles, data from
OCCP on disposition at discharge were supplemented
with information from the Alberta Ambulatory Care Cost-
ing project [21], the Canadian Diabetes Association [6],
the Heart Disease and Stroke Foundation of Canada
[22,23], Health Canada [23–25], Canadian clinical prac-
tice guidelines [26–28], other government and institu-
tional reports [29–33], provider survey data on day care
and cardiac rehabilitation, and peer-reviewed literature
[34–38]. In order to maintain consistency with the OCCP
data, Ontario provincial fee schedules and formulary [39–
41] were used as unit cost sources for physician-related
care, laboratory tests, and medications. Additional refer-
ences used for specific complications are noted within the
appropriate sections of this paper.
Reimbursement for health care in Canada is largely pro-
vincial rather than federal; therefore in order to derive
Table 1: ICD-9 codes used to identify inpatient groups. Diagnosis codes refer only to principal diagnosis or identifying procedure code
Complication ICD-9 code
AMI 410.00 – 410.91
Angina 413.0 – 413.9, 411.1
Ischemic Stroke 433.x1*, 434.xx¶, 436
TIA 435.9
1st LEA 84.10 – 84.17
2nd LEA 84.10 – 84.17
Diabetic Foot Ulcer 707.1
Hypoglycemia 250.8 x§
(ICD-9 = International Classification of Diseases, 9th revision, AMI = acute myocardial infarction, TIA = transient ischemic attack, LEA = lower 
extremity amputation) *x indicates that all fourth digits related to this root code were included. ¶xx indicates that all fourth and fifth digits related 
to this root code were included. §x indicates that all fifth digits related to this code were included.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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"national" costs, it was necessary to adjust provincial data.
Published health and personal care data from Statistics
Canada [42] were used to derive a ratio between provin-
cial and national healthcare costs by cost center for each
province. Provincial unit costs were then adjusted using
these ratios to derive the national equivalent.
There are several modalities of treatment for ESRD (e.g.,
hemodialysis, peritoneal dialysis, renal transplant). An-
nual costs of caring for patients on each of these were ap-
plied to the proportion of patients receiving that type of
treatment to give a weighted average cost. While the distri-
bution was taken from 1998 data, it was assumed that the
ESRD population is in a steady state – that is, the patients
leaving the ESRD populations and the patients entering
the ESRD population during a given year have approxi-
mately the same modality distribution such that the over-
all distribution does not vary significantly from year to
year. The distribution of treatment modalities for the
1998 Canadian ESRD population was obtained from the
Canadian Institute for Health Information [43–45]. There
is a definite and discernable event cost for renal transplant
versus the annual cost of managing someone who has had
a renal transplant. Thus, to estimate the steady-state cost
for ESRD, it was necessary to also estimate the costs of re-
nal transplantation. This was achieved by applying the
event year cost of a transplant to the proportion of pa-
tients who had received a renal transplant during 1998
(transplant year) and combining that with the annual
management cost applied to the proportion receiving a
transplant during a previous year. The average annual
costs of caring for a patient during the transplant year and
in a subsequent year were obtained from the literature
[46]. The average annual cost of treatment for hemodialy-
sis and that for peritoneal dialysis were taken from a 1998
report published by the Agence d'évaluation des technologies
et des modes d'intervention en santé (AÉTMIS) of Québec
[47]. These costs were updated to year 2000 and "nation-
alized" according to the methodology described above.
The majority of the unit cost and resource use data used in
this analysis were derived from Canadian sources. For rare
exceptions pertaining to post-acute care, it was necessary
to rely on resource use data from other sources. For exam-
ple, no Canadian data were available for post-acute care
following discharge from coronary artery bypass graft
(CABG) or percutaneous transluminal coronary angi-
oplasty (PTCA) readmissions in diabetic patients who had
a previous AMI. Thus, it was necessary to employ diagno-
sis-specific disposition distributions for a similar popula-
tion from five 1996/97 US all payer state databases to
derive initial post-acute care patterns. The proportions
were then adjusted to reflect the difference between Cana-
dian and US case fatality rates for diabetic patients with
AMI. Also, although initial discharge disposition data
from Canada were used in the analysis, Canadian data de-
tailing transitions to other levels of care over time for
those with disabling strokes were not available; therefore
Table 2: Typical event (first year) and state costs (subsequent annual cost) for complications (2000 $Canadian)
Complication Event Cost State Cost
Cardiovascular Disease
Acute myocardial infarction 18,635 1,193
Angina 3,183 1,485
Cerebrovascular Disease
Stroke 33,256 8,769
Transient Ischemic Attack 3,262 73
Nephropathy
Microalbuminuria 62 10
Gross proteinuria 54 18
End Stage Renal Disease - 63,045
Retinopathy --
Macular edema (ME) with photocoagulation 423 40
Proliferative retinopathy with photocoagulation 379 40
ME and proliferative retinopathy with photocoagulation 495 40
Blindness - 2,111
Neuropathy
Symptomatic neuropathy 148 -
Lower extremity amputation (LEA) 1 24,583 1,020
LEA 2 26,077 -
Episodic
Foot ulcer 2,183 -
Hypoglycemia 111 -BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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we used our stroke economic model [48] to derive the
state costs for stroke. The long-term transition data used in
this model come from Sweden [49].
Only direct medical costs, those directly related to delivery
of the health care service, are included in the estimates re-
ported here. All event and state cost estimates are reported
in 2000 Canadian dollars. Where 2000 values were not
available, older estimates were inflated using the Health
Care Inflation Index, a component of the Consumer Price
Index, supplied by Statistics Canada [42].
Results
Table 2 displays the state and event costs for the compli-
cations. Table 3 provides a cost breakdown of the event
year by management phases for those complications
where all or some of the patients were treated initially as
inpatients.
Macrovascular Complications
AMI
It was assumed that all patients with an AMI were treated
initially as inpatients. The acute care portion of the event
cost is comprised of acute hospitalization ($9,739), in-
cluding physician costs for the initial event and ambu-
lance costs ($237) for the 52% [17] of patients requiring
this type of transport to the hospital. Subsequent (post-
acute) care for AMI includes outpatient medical care, sur-
gical follow-up care post-CABG, home health care, cardiac
rehabilitation, long term facility care, and readmissions
within the event year for a subsequent myocardia infarc-
tion (MI), CABG, PTCA or coronary angiography. The
subsequent care cost was developed by weighting the cost
of these health care services by the proportion of patients
using these services to derive the average cost per person.
In other words, only those who had a CABG during their
stay would have the surgical follow-up care included in
their cost profile. The event year cost for AMI is $18,635.
State costs of AMI were calculated to be $1,193, per pa-
tient, per year on average. These include medications (i.e.,
aspirin, calcium antagonists, beta blockers, nitrates, angi-
otensin converting inhibitors, HMG-CoA reductase
inhibitors) weighted by the proportion of patients using
them, physician visits, and monitoring cardiology tests
(i.e., electrocardiogram (ECG) and stress test). A small
portion of diabetic patients who experienced an AMI (1.4
%) required long-term care facility placement according
to OCCP data. The cost of this care is also reflected in the
state cost. In addition to the sources listed previously, sev-
eral additional publications were used to obtain informa-
tion for the AMI resource use profiles [50–60].
Angina
On average, the event cost for angina is $3,183, per per-
son. This includes proportionately weighted estimates for
several sub-groups: unstable angina, hospitalized
($9,661); angina treated in emergency room or on an ur-
gent basis by a physician as an outpatient ($1,397); and
an acute anginal episode treated by usual care physician
($1,230). In the absence of Canadian-specific data, the ra-
tio of 3 stable to 1 unstable patient with angina [61], and
Table 3: Typical event year costs (2000 CAN$) by management phase for complications where hospitalization is, or may be, required.
Complication Hospital Other Care* Total Event Year
All Patients Treated as Inpatients Initially
AMI¶ $9,862 $8,773 $18,635
Stroke¶ $8,822 $24,434 $33,256
TIA $2,830 $432 $3,262
LEA 1 $15,996 $8,587 $24,583
LEA 2 $17,277 $8,800 $26,077
Patients Treated as Either Inpatient or Outpatient Initially
Angina¶: $991 $2,192 $3,183
Inpatient $3,613 $6,048 $9,661
Outpatient $240 $1,032 $1,272
DFU: $1,957 $226 $2,183
Inpatient $6,475 $1,327 $7,802
Outpatient $1,042 $1,042
Hypoglycemia $110 $1 $111
Inpatient $4,142 $42 $4,184
Outpatient $71 $71
(AMI = acute myocardial infarction, DFU = diabetic foot ulcer, LEA1 = first lower extremity amputation, LEA2 = second lower extremity amputa-
tion, TIA = transient ischemic attack) * Other Care includes all outpatient services for all patients. For those treated initially as inpatients, other 
care also includes sub-acute inpatient, home health and day care services where applicable. ¶Includes pre-admission CPR/ambulance and hospital 
care.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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the 96% proportion of unstable patients treated as inpa-
tients were obtained from the literature [62]. OCCP data
revealed that of those admitted with angina, 28% were
transported by ambulance. Subsequent first year costs in-
clude the same cost centers as for AMI except that no pa-
tients became residents of a nursing home as a result. The
medications included in the angina resource use profile
include aspirin, calcium antagonists, beta blockers, ni-
trates, angiotensin converting inhibitors and statins. The
costs for these drugs were weighted based on reported
proportions of angina patients using them [54,59,63].
State costs of angina were calculated to be $1,485, per pa-
tient, per year on average. These included medications,
physician visits, laboratory tests and monitoring cardiolo-
gy tests (i.e., ECG and stress test). Additional resource use
information regarding visits and tests was abstracted from
published sources [27,64,65].
Ischemic Stroke
The disabling consequences of stroke are reflected in the
first year management costs, as more patients require con-
tinuing care services after discharge from the hospital.
OCCP data and information from published literature
[66–71] were used to determine post-acute care place-
ment for rehabilitation, readmission for a subsequent
stroke events and long term care in the first year. Acute
care comprises only 27% ($8,822) of the mean event cost
for ischemic stroke ($33,256). This is half of the AMI pro-
portion (53%), highlighting the effect of increased need
for post-acute care in stroke.
The mean annual state cost is $8,769 and reflects outpa-
tient monitoring, medications (i.e., aspirin) and the in-
creased need for day care, durable medical equipment and
permanent long-term care in this patient population.
TIA
It was assumed for this analysis that all patients diagnosed
with a TIA who are diabetic would receive inpatient care
initially. It was also assumed that all TIAs are truly tran-
sient – an assumption that finds some support in the
OCCP TIA data where the only post-acute discharge dis-
positions were home (outpatient care), home health care
and rehabilitation. Thus, no health care services associat-
ed with permanent residual disability (e.g., long term care
placement) were considered for inclusion in the cost esti-
mate. Additional resource use data were obtained from
Nova Scotia [72]. The mean event cost for TIA is $3,262.
Aspirin is the only medication included in the cost pro-
files for TIA. Thus, the mean state cost of $73 for TIA is
based on monitoring visits to a physician and daily
aspirin.
Microvascular Complications
Nephropathy
The costs for microalbuminuria and gross proteinuria are
based primarily on recommendations from Canadian
clinical practice guidelines and consist only of laboratory
tests on urine and physician visits. The use of ACE Inhibi-
tors is discussed in the literature with regard to the preven-
tion of progression of renal disease. The Canadian clinical
practice recommendations of 1998 recognize that some
patients with type 2 diabetes who have proteinuria may
benefit from this type of therapy [27] and suggest that
ACE Inhibitors should be considered, but do not recom-
mend them for all patients. As no data are available per-
taining to the proportion of patients on this type of
therapy solely for the purpose of preventing further renal
deterioration, the cost is not included in the current esti-
mate. The event cost for microalbuminuria is $62; $54 for
gross proteinuria. The state costs are $10 and $18 for
microalbuminuria and gross proteinuria, respectively.
The annual cost ($63,045) of caring for a patient with
ESRD represents a weighted average of the annual costs
for hemodialysis, peritoneal dialysis, and renal transplant.
Retinopathy
The costs for macular edema and proliferative retinopathy
are comprised of physician visits, ophthalmology con-
sults, and the use of diagnostic and therapeutic eye proce-
dures (i.e., color fundus photography, fluorescein
angiography and photocoagulation). Published Canadian
clinical practice guidelines for diabetic retinopathy were
the source for resource use [27,28]. The mean event costs
for these complications are $423 for macular edema and
$379 for proliferative retinopathy, respectively when pho-
tocoagulation is used. If both conditions are present in
one patient, the event cost rises to $495. The state cost of
$40, comprised of additional monitoring by an ophthal-
mologist, is the same for both conditions.
Blindness does not have an event cost, as there is no event
per se. Rather, the decent into blindness due to diabetes is
the result of either failure to detect or failure to treat retin-
opathy at an earlier stage. Unfortunately, there has been
little information developed on the annual cost of blind-
ness, let alone the annual direct medical cost in any coun-
try. No information could be found from the literature,
government agencies or relevant private agencies that deal
with the blind. One of the only available sources for direct
medical costs is a published US-based cost from 1990
[73]. By converting this figure to Canadian dollars using
the 1990 exchange rate of $0.8572 and then inflating the
Canadian value to a 2000 Canadian dollar values a state
cost of $2,111 for blindness was estimated.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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Neuropathy
Three levels of neuropathy were examined in this analysis:
symptomatic neuropathy, and first and second LEA. The
resource use for symptomatic neuropathy was limited to
diagnosis and monitoring, as there is no specific treat-
ment for this condition, and use of the palliative options
available is not consistent. Thus, this is likely an underes-
timation of the cost for this complication. Published clin-
ical practice guidelines were used to establish the event
year resource use profile [27,28,74]. The event year cost is
$148 per person. There is no state cost as beyond the ini-
tial diagnostic tests, there is no further management
recommended.
Neuropathy and foot ulcers can lead to amputations.
These can occur at various levels: toe, foot, below the knee
and above the knee. Thus, the cost for each type of ampu-
tation was calculated using OCCP data and then weighted
by the proportion of diabetic patients having that type of
surgery to determine the overall event cost for a LEA. Fur-
thermore, it has been reported that 50% of patients with
diabetes who have a LEA will go on to have a second LEA
within 5 years [75]; therefore, event costs for a first and
second amputation were calculated separately. As it is not
possible to discern first versus second LEA in a claims da-
tabase, proportions by type of amputation were used to
differentiate between first and second amputation inpa-
tient costs. No Canadian data were available to make this
differentiation possible at all of the necessary levels re-
quired for this analysis; therefore, a US based study from
Rochester, MN was used to provide proportions of ampu-
tation type for first and second LEA [76]. The cost of an
above the knee amputation (AKA) is considerably more
than that of a toe amputation, not just in the hospital
($19,760 versus $6,460) but also beyond due to the sig-
nificantly higher level of disability resulting from an AKA.
Information regarding post-acute care dispositions, reha-
bilitation, readmissions for debridement and major
stump revisions, and use of prosthetic devises and durable
medical equipment were obtained from the OCCP data-
base, provider surveys and publications [77–79]. The in-
crease in event cost from first ($24,583) to second
($26,077) represents a shift to a higher anatomical, and
thus, more costly level of amputation for the second am-
putation as noted in the Rochester study [76].
LEA can be a very disabling event for a patient and has
consequences beyond the event year. No published infor-
mation was identified that could isolate ongoing annual
direct management costs related to LEA versus usual man-
agement of a patient with diabetes, thus, only costs direct-
ly related to the LEA (i.e., long-term facility residential
care and the management, refitting of the prosthetic de-
vice) are included in the state cost for LEA. The state cost
for LEA 1 is $1,020. To avoid double-counting, given the
cost components of the LEA state profile, the state cost of
the second LEA is conservatively assumed to be zero as it
was not possible to discern which prosthesis related costs
would be specific to the second prosthesis versus costs al-
ready included in the state cost for LEA1[77,80–82].
Diabetic Foot Ulcer
For the purpose of this analysis, foot ulcers are defined as
those that heal without amputation or vascular surgery.
Since not all diabetic foot ulcers are treated in an inpatient
setting, the event cost is a weighted average of inpatient
($7,802) and outpatient care costs ($1,042). OCCP data
and information from the literature were used to deter-
mine proportions and resource use [21,83–85]. The event
cost for diabetic foot ulcer is $2,183 per person, on aver-
age. There is no state cost calculated for this complication
as it is considered to be episodic.
Hypoglycemia
For the purpose of this analysis, only hypoglycemic events
that generate the use of medication or formal health care
services (formal care) were included. Three levels of re-
source use were considered for this condition: the lowest
level of formal care is self-treatment with a glucagon injec-
tion and no intervention from medical personnel ($24);
the middle level is an ambulatory care or emergency room
consultation ($194); the highest level is hospitalization
with a follow-up physician visit ($4,184). A cost was de-
veloped for each level. An overall hypoglycemic event cost
was derived by applying the appropriate weights, taken
from US studies, as no Canadian data were available
[86,87]. Only 1% of those experiencing a hypoglycemic
event are assigned inpatient costs. The event cost for this
episodic complication is $111.
Discussion
Diabetes and its complications are major health care
problems for Canada. Nearly 6% of the Canadian popula-
tion is affected and First Nations have one of the highest
reported prevalences (26%) in an indigenous population
[88]. It has been recognized that health care expenditures
related to the complications of diabetes account for a sub-
stantial proportion of the public health care budget [89]
and that related costs are likely to escalate as the popula-
tion ages. Yet, given the size of the problem, the acknowl-
edged concern and initiatives undertaken to address
diabetes on a national level and for the native Canadian
population in particular, it is surprising that there is so
little available Canadian information about the cost of the
complications of diabetes, particularly at a level detailed
enough to be meaningful to decision makers or those do-
ing economic analyses. The purpose of this paper is to
provide comprehensive cost estimates for several com-
mon complications of diabetes in a manner that can be
useful to interested parties.BMC Health Services Research 2003, 3 http://www.biomedcentral.com/1472-6963/3/7
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A main goal of this analysis was to develop Canadian-spe-
cific cost estimates using Canadian unit cost and resource
use information wherever possible. This point is stressed
as the importance of using country-specific data in an eco-
nomic analysis cannot be ignored. As noted earlier, it is
not uncommon to find US or European costs for diabetes
used as a proxy for Canadian costs, even in official reports
[6]; however, the true relevance of these costs to a Canadi-
an population can only be assumed. In previously pub-
lished work [12], we have shown that the use of US data,
even when Canadian unit costs are used can lead to inac-
curate, albeit well-intentioned estimates. In that example,
a difference of approximately $1,400 dollars in the state
cost for stroke was noted when US resource use data were
replaced with Canadian data. As the state cost is applied
to every year the patient is in that health state, a substan-
tial miscalculation of the lifetime cost attributed to stroke
would have been produced, even though it would have
been based on the best available data and accepted as a
reasonable proxy in the absence of Canadian data.
Although there may be clinical consensus on the manage-
ment of a condition, type and availability of health care
services, medical practice patterns, and access to care will
affect the type and level of care actually delivered. Thus,
differences beyond those relating to just monetary condi-
tions must be acknowledged when using proxy data, as
sometimes their use is unavoidable. While every effort
was made to use only Canadian-based data in this analy-
sis, it was not possible in some cases (e.g., aspects of LEA
and of AMI). Does that mean that those estimates relying
on some data from elsewhere should be ignored? We
would argue "no" even in the face of the cautionary words
provided above. All unit costs used in this analysis are
from Canadian sources and the vast majority of resource
use data are also Canadian. The estimates provided here
are the closest reflection possible of the costs for these
complications in Canada given the data available at the
time of the analysis. They can and should be used, but
with an understanding that for the few estimates where
proxy data have been employed, the cost may not be a pre-
cise estimate for Canada.
Apart from the use of proxy data, some of the complica-
tion costs may be overestimated or underestimated due to
the content of the resource use profile. For example, the
TIA estimate may be an overestimation of the event cost if
a substantial number of such patients are not treated in
the hospital initially in Canada. If the TIA profile were to
include a large proportion of patients treated initially as
outpatients, the event cost for TIA could be decreased by
as much as 45% [16,90]. It is likely that the foot ulcer, LEA
and symptomatic neuropathy estimates are underestimat-
ed as data for some potentially relevant cost components
were not available. The degree of uncertainty in these esti-
mates cannot be quantified because in most cases the
source data do not provide it and there are reasons other
than statistical imprecision that may also contribute.
The use of administrative databases, as in this analysis,
brings with it concern regarding the accuracy of ICD-9
coding. Published coding error rates relating to diabetes in
Canada could not be identified. While a study from the
U.K. in the early 1990s showed that there was under-cod-
ing of diabetes in hospital records [91], later studies from
the US have reported a greater than 90% accuracy rate in
coding of major macrovascular complications in diabetic
patients [92]. The coding error rate in the OCCP data is
unknown, but for the purpose of this analysis, it is only of
concern if there is a cost-relevant bias in the cases includ-
ed. It is unclear whether such a bias exists. Ideal circum-
stances would allow for the development of cost estimates
based on a comprehensive study, designed not to influ-
ence resource use, of unselected patients with sufficient
follow-up. Unfortunately, that ideal rarely exists. This cost
estimate created by assembling existing Canadian data
provides health care decision makers in Canada, who can-
not wait for the ideal data to accumulate, key information
heretofore unavailable.
Conclusion
While health care promotion and education are valuable
tools in the fight against diabetes, the condition and its
complications will continue to have a profound impact
on the health of Canadians, as well as provincial and na-
tional health care budgets for the foreseeable future. New
treatments are being developed to improve glycemic con-
trol in those with diabetes with the goal of preventing or
delaying some of the devastating complications associat-
ed with the disease. While appropriate medical care of the
patient should be the prevailing factor for all health care
decision makers, whether at the care delivery or the policy
level, economic factors cannot be ignored. In order to de-
termine which therapeutic agents are appropriate for use,
cost-effectiveness, as well as efficacy and safety should be
weighed. The estimates in this analysis do not provide
cost-effectiveness information for any type of treatment
for diabetes, but we believe that they do provide valuable
cost inputs for any researcher or policy maker who needs
such information to carry out an economic analysis.
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